...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques
【24h】

Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques

机译：用植物来源的单克隆抗体延迟治疗埃博拉病毒感染可为猕猴提供保护

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Filovirus infections can cause a severe and often fatal disease in humans and nonhuman primates, including great apes. Here, three anti-Ebola virus mouse/human chimeric mAbs (c13C6, h-13F6, and c6D8) were produced in Chinese hamster ovary and in whole plant (Nicotiana benthamiana) cells. In pilot experiments testing a mixture of the three mAbs (MB-003), we found that MB-003 produced in both manufacturing systems protected rhesus macaques from lethal challenge when administered 1 h postinfection. In a pivotal follow-up experiment, we found significant protection (P < 0.05) when MB-003 treatment began 24 or 48 h postinfection (four of six survived vs. zero of two controls). In all experiments, surviving animals that received MB-003 experienced little to no viremia and had few, if any, of the clinical symptoms observed in the controls. The results represent successful postexposure in vivo efficacy by a mAb mixture and suggest that this immunoprotectant should be further pursued as a postexposure and potential therapeutic for Eboia virus exposure.
机译：丝状病毒感染可在人类和非人类灵长类动物（包括大猿）中引起严重且通常是致命的疾病。在这里，在中国仓鼠卵巢和整个植物（本氏烟草）细胞中产生了三种抗埃博拉病毒小鼠/人嵌合mAb（c13C6，h-13F6和c6D8）。在测试这三种mAb（MB-003）混合物的中试实验中，我们发现，在两个生产系统中生产的MB-003在感染后1 h给药时都可以保护猕猴免受致命的攻击。在一项关键的后续实验中，当MB-003治疗在感染后24或48小时开始时，我们发现了显着的保护作用（P <0.05）（六个存活中的四个存活，而两个对照组中的零个存活）。在所有实验中，接受MB-003存活的动物几乎没有病毒血症，甚至在对照组中也没有观察到临床症状。结果表明mAb混合物具有成功的体内暴露后功效，并建议应进一步追求该免疫保护剂作为埃博雅病毒暴露的暴露后和潜在治疗剂。

著录项

  • 来源
  • 作者

    Gene Garrard Olinger; James Pettitt; Do Kim; Cara Working; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D. Hume; Ashley K. Johnson; Josh Morton; Michael Pauly; Kevin J. Whaley; Calli M. Lear; Julia E. Biggins; Corinne Scully; Lisa Hensley; Larry Zeitlin;

  • 作者单位

    Division of Virology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;

    Division of Virology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;

    Mapp Biopharmaceutical, Inc., San Diego, CA 92121;

    Kentucky BioProcessing, LLC, Owensboro, KY 42301;

    Office of the Chief Scientist, US Food and Drug Administration, Medical Science Countermeasures Initiative, Silver Spring, MD 20993;

    Kentucky BioProcessing, LLC, Owensboro, KY 42301;

    Kentucky BioProcessing, LLC, Owensboro, KY 42301;

    Kentucky BioProcessing, LLC, Owensboro, KY 42301;

    Kentucky BioProcessing, LLC, Owensboro, KY 42301;

    Kentucky BioProcessing, LLC, Owensboro, KY 42301;

    Mapp Biopharmaceutical, Inc., San Diego, CA 92121;

    Mapp Biopharmaceutical, Inc., San Diego, CA 92121;

    Division of Virology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;

    Division of Virology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;

    Division of Virology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702;

    Division of Virology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702,Office of the Chief Scientist, US Food and Drug Administration, Medical Science Countermeasures Initiative, Silver Spring, MD 20993;

    Mapp Biopharmaceutical, Inc., San Diego, CA 92121;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    passive immunization; therapy;

    机译：被动免疫治疗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号